Hansa Biopharma Logo

Hansa Biopharma

Develops antibody-cleaving enzymes to treat rare diseases and enable organ transplants.

HNSA | ST

Overview

Corporate Details

ISIN(s):
SE0002148817 (+1 more)
LEI:
549300LLEO25ZJJ3NT91
Country:
Sweden
Address:
Box 785, 220 07 Lund
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Hansa Biopharma is a commercial-stage biopharmaceutical company that develops and commercializes innovative immunomodulating therapies for rare immunological diseases. The company's core focus is its proprietary antibody-cleaving enzyme technology, which targets and inactivates immunoglobulin G (IgG) antibodies to inhibit harmful immune responses. This technology enables life-saving procedures, such as kidney transplantation for highly sensitized patients, and is being developed to treat a range of acute IgG-mediated autoimmune conditions. Key products include the enzyme imilfidase. The company's strategy involves drug discovery, development, commercialization, and partnerships to address significant unmet medical needs in transplantation and autoimmunity.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-10-31 14:37
Major Shareholding Notification
Swedish 10.7 KB
2025-10-31 12:00
Share Issue/Capital Change
Hansa Biopharma: Ökning av antalet aktier och röster
Swedish 188.6 KB
2025-10-31 12:00
Declaration of Voting Results & Voting Rights Announcements
Hansa Biopharma: Increase in number of shares and votes
English 190.3 KB
2025-10-30 07:00
Interim Report
Swedish 1.7 MB
2025-10-30 07:00
Interim Report
English 2.1 MB
2025-10-08 17:06
Major Shareholding Notification
Swedish 10.8 KB
2025-10-07 10:02
Major Shareholding Notification
Swedish 10.9 KB
2025-10-06 17:53
Major Shareholding Notification
Swedish 10.0 KB
2025-10-06 15:46
Major Shareholding Notification
Swedish 10.1 KB
2025-10-03 17:20
Major Shareholding Notification
Swedish 12.4 KB
2025-10-02 08:30
Share Issue/Capital Change
Hansa Biopharma publishes disclosure document for admission to trading of share…
English 193.8 KB
2025-10-02 08:30
Share Issue/Capital Change
Hansa Biopharma publicerar informationsdokument för upptagande till handel av a…
Swedish 173.9 KB
2025-10-02 00:15
Share Issue/Capital Change
Hansa Biopharma has carried out a directed share issue of 17 million shares, ra…
English 231.2 KB
2025-10-02 00:15
Share Issue/Capital Change
Hansa Biopharma har genomfört en riktad emission av 17 miljoner aktier, vilket …
Swedish 226.1 KB
2025-10-01 17:31
Share Issue/Capital Change
Hansa Biopharma avser genomföra en riktad nyemission om cirka 60 miljoner USD
Swedish 212.4 KB

Automate Your Workflow. Get a real-time feed of all Hansa Biopharma filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Hansa Biopharma

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Hansa Biopharma via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2024-06-17 Anne Säfström Lanner Other Sell 10,487 443,285.49 SEK
2024-06-17 Sören Tulstrup Other Sell 9,199 388,841.73 SEK
2024-06-17 Sören Tulstrup Other Buy 35,200 N/A
2022-07-19 Peter Nicklin Other Buy 14,500 1,032,192.68 SEK
2022-06-17 Christian Kjellman Other Buy 6,915 345,680.85 SEK
2022-06-17 Donato Spota Other Sell 4,638 231,853.62 SEK
2022-06-17 Christian Kjellman Other Sell 4,002 200,059.98 SEK
2022-06-17 Sören Tulstrup Other Sell 3,925 196,210.75 SEK
2022-06-17 Sören Tulstrup Other Buy 3,925 196,210.75 SEK
2022-06-17 Anne Säfström Lanner Other Sell 2,685 134,223.15 SEK

Peer Companies

Active Biotech Logo
Develops immunology-based drugs for cancer and inflammatory diseases with high unmet medical need.
Sweden
ACTI
ACTUATE THERAPEUTICS, INC. Logo
Clinical-stage biopharma developing a novel GSK-3 inhibitor for hard-to-treat cancers.
United States of America
ACTU
AcuCort AB Logo
Develops a rapid oral film for acute allergies, croup, and chemo-induced nausea.
Sweden
ACUC
Acurx Pharmaceuticals, Inc. Logo
Developing a new class of antibiotics to treat priority Gram-positive bacterial infections.
United States of America
ACXP
Adagene Inc. Logo
Develops novel antibody-based immunotherapies for cancer using an AI-driven discovery platform.
United States of America
ADAG
Adaptimmune Therapeutics PLC Logo
Develops novel T-cell therapies to treat solid tumors by engineering a patient's own immune cells.
United States of America
ADAP
ADBIOTECH Co.,Ltd. Logo
Develops egg-based IgY antibodies as vaccine/antibiotic alternatives for animal and human health.
South Korea
179530
ADC Therapeutics SA Logo
Develops targeted antibody-drug conjugates for hematological and solid tumors.
United States of America
ADCT
ADIAL PHARMACEUTICALS, INC. Logo
Develops personalized, genetically-targeted drugs for treating Alcohol Use Disorder and addiction.
United States of America
ADIL
Adicet Bio, Inc. Logo
Developing off-the-shelf gamma delta T cell therapies for cancer and autoimmune diseases.
United States of America
ACET

Talk to a Data Expert

Have a question? We'll get back to you promptly.